The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease.
Dharminder Chauhan
Consultant or Advisory Role - Stemline Therapeutics
Arghya Ray
No relevant relationships to disclose
Deepika Sharma Das
No relevant relationships to disclose
Vincent Macri
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Christopher Brooks
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Paul G. Richardson
No relevant relationships to disclose
Eric K. Rowinsky
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Kenneth Carl Anderson
No relevant relationships to disclose